Examples: breast cancer, NCT03147287, pd-l1

Top 100 results for: "lung cancer"

Not Enrolling

Phase 1/2 Study of PF-06463922 (AN ALK/ROSI Tyrosine Kinase Inhibitor) in Patients with Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations

Trial Description: Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non small cell lung cancer patients .

  • Conditions: alk-positive non small cell lung cancer (nsclc) and ros1-positive nsclc
  • Phase: I/II
  • Trial ID: NCT01970865
  • Protocol ID: 13-408

Not Enrolling

A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer, Melanoma and Mismatch Repair-Proficient Colorectal Cancer

Trial Description: The purpose of this study is to determine the safety and tolerability of entinostat used in combination with pembrolizumab in patients with Non-small Cell Lung Cancer. Additionally, the purpose of the study is to assess how effective entinostat and pembrolizumab are in combination in patients with Non-small Cell Lung Cancer, Melanoma, and Mismatch-Repair Proficient Colorectal Cancer

  • Conditions: melanoma, mismatch repair-proficient colorectal cancer, non-small cell lung cancer
  • Phase: I/II
  • Trial ID: NCT02437136
  • Protocol ID: 15-322

Not Enrolling

Brief Behavioral Intervention for Dyspnea in Patients with Advanced Lung Cancer

Trial Description: This research study is evaluating a behavioral intervention designed to help people with advanced lung cancer manage dyspnea (i.e., breathlessness or shortness-of-breath).

  • Conditions: lung cancer
  • Phase: Not Applicable
  • Trial ID: NCT03089125
  • Protocol ID: 16-476

Not Enrolling

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)- A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Trial Description: This phase III ALCHEMIST treatment trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

  • Conditions: stage ib lung non-small cell carcinoma ajcc v7, stage ii lung non-small cell cancer ajcc v7, stage iia lung non-small cell carcinoma ajcc v7, stage iib lung non-small cell carcinoma ajcc v7, stage iiia lung non-small cell cancer ajcc v7
  • Phase: III
  • Trial ID: NCT02595944
  • Protocol ID: 16-723

Not Enrolling

Phase I/II Study of Olaparib and Temozolomide in Patients with Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy

Trial Description: This research study is evaluating the combination of olaparib and temozolomide as a possible treatment for Small Cell Lung Cancer.

  • Conditions: small cell lung cancer
  • Phase: I/II
  • Trial ID: NCT02446704
  • Protocol ID: 15-121

Enrolling

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Trial Description: This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

  • Conditions: lung adenocarcinoma, lung large cell carcinoma, resectable lung non-small cell carcinoma, stage ib lung non-small cell carcinoma ajcc v7, stage ib lung squamous cell carcinoma ajcc v7, stage ii lung non-small cell cancer ajcc v7, stage ii lung squamous cell carcinoma ajcc v7, stage iia lung non-small cell carcinoma ajcc v7, stage iia lung squamous cell carcinoma ajcc v7, stage iib lung non-small cell carcinoma ajcc v7, stage iib lung squamous cell carcinoma ajcc v7, stage iiia lung non-small cell cancer ajcc v7, stage iiia lung squamous cell carcinoma ajcc v7
  • Phase: III
  • Trial ID: NCT02194738
  • Protocol ID: 15-700

Enrolling

Comparative Effectiveness of Early Integrated Telehealth versus In-Person Palliative Care for Patients with Advanced Lung Cancer

Trial Description: This research study is evaluating ways to provide palliative care to patients who have recently been diagnosed with lung cancer and their families.

  • Conditions: lung cancer
  • Phase: Not Applicable
  • Trial ID: NCT03375489
  • Protocol ID: 17-484

Not Enrolling

A Phase II Study of Nivolumab in Combination with Carboplatin and Pemetrexed, with or without Bevacizumab, in Patients with Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer

Trial Description: This research study is studying a drug intervention as a possible treatment for lung cancer. The drugs involved in this study are: - Nivolumab - Carboplatin - Pemetrexed - Ipilimumab

  • Conditions: lung cancer
  • Phase: II
  • Trial ID: NCT03256136
  • Protocol ID: 17-011

Enrolling

Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination wtih the MEK Inhibitor Binimetinib (MEK162) for Patients with Advanced KRAS Mutant Non-Small Cell Lung Cancer

Trial Description: This trial is being conducted as a possible treatment for lung cancer with a specific change in the KRAS gene. The drugs involved in this study are: - Palbociclib - Binimetinib

  • Conditions: lung cancer
  • Phase: I/II
  • Trial ID: NCT03170206
  • Protocol ID: 16-531

Enrolling

Phase 1 Study of Niraparib in Combination with Osimertinib in EGFR-Mutated Advanced Lung Cancer

Trial Description: This research study is studying a combination of drugs as a possible treatment for EGFR-Mutated Advanced Lung Cancer. The names of the study drugs involved in this study are Niraparib and Osimertinib.

  • Conditions: lung cancer
  • Phase: I
  • Trial ID: NCT03891615
  • Protocol ID: 18-613

Enrolling

Randomized Trial of an Intervention to Enhance Quality of Life in Adults Completing Lung Cancer Treatment with Curative Intent

Trial Description: The aim of this study is to evaluate the efficacy of a brief psychoeducational intervention to improve quality of life in patients with lung cancer who are transitioning from active treatment to surveillance.

  • Conditions: lung cancer
  • Phase: Not Applicable
  • Trial ID: NCT05087251
  • Protocol ID: 21-426

Not Enrolling

Phase 1b Study of LY3295668 erbumine Monotherapy in Patients with Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer

Trial Description: The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.

  • Conditions: small cell lung cancer
  • Phase: I
  • Trial ID: NCT03898791
  • Protocol ID: 19-246

Not Enrolling

Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer with Actionable Genomic Alterations and Progressed On or After Applicable Targeted Therapy and Platinum-based Chemotherapy (TROPION-Lung05)

Trial Description: This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with known actionable genomic alterations.

  • Conditions: non-small cell lung cancer
  • Phase: II
  • Trial ID: NCT04484142
  • Protocol ID: 20-602

Enrolling

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)

Trial Description: This study will assess the safety and efficacy of VS-6766 monotherapy or VS-6766 in combination with defactinib in subjects with recurrent Non-small cell lung cancer.

  • Conditions: kras activating mutation, non small cell lung cancer
  • Phase: II
  • Trial ID: NCT04620330
  • Protocol ID: 21-174

Not Enrolling

Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide

Trial Description: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as etoposide, carboplatin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which radiation therapy regimen is more effective when given together with chemotherapy in treating patients with limited-stage small cell lung cancer. This randomized phase III trial is comparing different chest radiation therapy regimens to see how well they work in treating patients with limited-stage small cell lung cancer.

  • Conditions: lung cancer
  • Phase: III
  • Trial ID: NCT00632853
  • Protocol ID: 12-134

Not Enrolling

Afatinib sequenced with concurrent chemotherapy and radiation in EGFR-Mutant non-small cell lung tumors: The ASCENT trial

. Chemotherapy and radiation is the standard treatment for the patients with stage III non-small cell lung cancer (NSCLC). For people with epidermal growth factor receptor (EGFR) mutations, adding a type of drug called a tyrosine kinase inhibitor (TKI) can help increase the response to treatment. Afatinib is a tyrosine kinase inhibitor. It has been studied in a previous research study in participants with more advanced NSCLC. Results from that study indicate it may be helpful in treating NSCLC with EGFR mutations. In this study, patients with stage III NSCLC and EGFR mutations will receive

  • Conditions: lung cancer
  • Phase: II
  • Trial ID: NCT01553942
  • Protocol ID: 11-464

Not Enrolling

Biomarkers of response to ipilimumab and nivolumab as first-line therapy for metastatic non-small cell lung cancer (NSCLC): an open-label, single arm phase 2 study

Trial Description: This research study is studying two immunotherapy drugs as a possible treatment for advanced non-small cell lung cancer (NSCLC). The drugs involved in this study are: - Ipilimumab - Nivolumab

  • Conditions: non-small cell lung cancer
  • Phase: II
  • Trial ID: NCT03425331
  • Protocol ID: 17-566

Not Enrolling

A Phase II study of Lorlatinib (PF-06463922) in advanced ALK and ROS1 rearranged NSCLC with CNS metastasis in the absence of measurable extracranial lesions

Trial Description: This research study is studying a drug as a possible treatment for ALK-positive or ROS1-positive non-small cell lung cancer (NSCLC). The following drug will be involved in this study : - Lorlatinib

  • Conditions: non-small cell lung cancer (nsclc)
  • Phase: II
  • Trial ID: NCT02927340
  • Protocol ID: 16-248

Not Enrolling

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer

Trial Description: This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer

  • Conditions: metastatic non small cell lung cancer
  • Phase: II
  • Trial ID: NCT04614103
  • Protocol ID: 20-647

Enrolling

Randomized Trial of a Supportive Care Mobile Application to Improve Symptoms, Coping, and Quality of Life in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Trial Description: This research study is looking at the role of a supportive care mobile app in improving symptoms, coping skills, and quality of life in patients with non-small cell lung cancer.

  • Conditions: coping skills, non small cell lung cancer, quality of life
  • Phase: I/II
  • Trial ID: NCT04629300
  • Protocol ID: 20-398

Not Enrolling

A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer

Trial Description: The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.

  • Conditions: carcinoma non-small-cell lung
  • Phase: III
  • Trial ID: NCT04025879
  • Protocol ID: 19-507

Not Enrolling

A Phase IB/II Study of Alectinib Combined with Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

Trial Description: This research study is studying a drug combination as a possible treatment for anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer. The drugs involved in this study are: - Alectinib - Cobimetinib

  • Conditions: non-small cell lung cancer
  • Phase: I/II
  • Trial ID: NCT03202940
  • Protocol ID: 17-112

Not Enrolling

A Phase 2 Study of osimertinib in combination with selumetinib in EGFR inhibitor naïve advanced EGFR mutant lung cancer

Trial Description: This research study is studying a combination of two targeted therapies as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The drugs involved in this study are: - Osimertinib (Tagrisso) - Selumetinib

  • Conditions: non-small cell lung cancer
  • Phase: II
  • Trial ID: NCT03392246
  • Protocol ID: 17-540

Not Enrolling

A Phase 1/2 Study of osimertinib in combination or alternating with gefitinib in EGFR inhibitor naïve advanced EGFR mutant lung cancer

Trial Description: This research study is studying a combination of two drugs as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The interventions involved in this study are: - Osimertinib (Tagrisso) - Gefitinib (Iressa)

  • Conditions: non-small cell lung cancer
  • Phase: I
  • Trial ID: NCT03122717
  • Protocol ID: 16-627

Enrolling

A Phase 2 Study of osimertinib with on-study and post-progression biopsy in the first line treatment of EGFR inhibitor naïve advanced EGFR mutant lung cancer

Trial Description: This research study is studying a targeted therapy as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The names of the study drug involved in this study is: - Osimertinib (Tagrisso)

  • Conditions: carcinoma non-small-cell lung
  • Phase: II
  • Trial ID: NCT03586453
  • Protocol ID: 18-070

Not Enrolling

PHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS DOCETAXEL IN PREVIOUSLY TREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH OR WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG01)

Trial Description: This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations.

  • Conditions: non-small cell lung cancer
  • Phase: III
  • Trial ID: NCT04656652
  • Protocol ID: 20-724

Not Enrolling

"A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors

Trial Description: This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable), including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also block the flow of oxygen to the tumor, and may help make the tumor more sensitive to olaparib.

  • Conditions: metastatic lung non-small cell carcinoma, metastatic lung small cell carcinoma, metastatic pancreatic adenocarcinoma, metastatic triple-negative breast carcinoma, pancreatic ductal adenocarcinoma, stage iii breast cancer ajcc v7, stage iii lung non-small cell cancer ajcc v7, stage iii lung small cell carcinoma ajcc v7, stage iii pancreatic cancer ajcc v6 and v7, stage iiia breast cancer ajcc v7, stage iiia lung non-small cell cancer ajcc v7, stage iiia lung small cell carcinoma ajcc v7, stage iiib breast cancer ajcc v7, stage iiib lung non-small cell cancer ajcc v7, stage iiib lung small cell carcinoma ajcc v7, stage iiic breast cancer ajcc v7, stage iv breast cancer ajcc v6 and v7, stage iv lung non-small cell cancer ajcc v7, stage iv lung small cell carcinoma ajcc v7, stage iv pancreatic cancer ajcc v6 and v7, triple-negative breast carcinoma, unresectable lung small cell carcinoma, unresectable pancreatic adenocarcinoma, unresectable pancreatic carcinoma, unresectable triple-negative breast carcinoma
  • Phase: II
  • Trial ID: NCT02498613
  • Protocol ID: 18-714

Enrolling

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Trial Description: This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.

  • Conditions: alk gene rearrangement, alk gene translocation, alk positive, stage ib non-small cell lung carcinoma ajcc v7, stage ii non-small cell lung cancer ajcc v7, stage iia non-small cell lung carcinoma ajcc v7, stage iib non-small cell lung carcinoma ajcc v7, stage iiia non-small cell lung cancer ajcc v7
  • Phase: III
  • Trial ID: NCT02201992
  • Protocol ID: 15-702

Not Enrolling

A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

Trial Description: This study is an open-label Phase 1/ 2 evaluation of CB-839 in combination with nivolumab in patients with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.

  • Conditions: clear cell renal cell carcinoma (ccrcc), melanoma, non-small cell lung cancer (nsclc)
  • Phase: I/II
  • Trial ID: NCT02771626
  • Protocol ID: 16-379

Enrolling

A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lun

Trial Description: This is a Phase III, randomised, controlled, 3-arm, multi-centre study of neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy alone, for the treatment of patients with resectable EGFRm Non-Small Cell Lung Cancer

  • Conditions: non-small cell lung cancer
  • Phase: III
  • Trial ID: NCT04351555
  • Protocol ID: 21-565

Enrolling

A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progressed on First-Line Osimertinib Therapy (ORCHARD)

Trial Description: Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.

  • Conditions: non-small cell lung cancer
  • Phase: II
  • Trial ID: NCT03944772
  • Protocol ID: 19-368

Not Enrolling

A Phase 1/2 Study of REGN5093 in Patients with MET-Altered Advanced Non-Small Cell Lung Cancer

Trial Description: The primary objective of the dose escalation (phase 1) part of the study is to assess the safety, tolerability, and pharmacokinetics (PK) of REGN5093 for determination of the maximum tolerated dose (MTD) and/or definition of the recommended phase 2 dose (RP2D) of REGN5093 in patients with MET-altered Non-small cell lung cancer (NSCLC). The primary objective of the dose expansion (phase 2) part of the study is to assess preliminary anti-tumor activity of REGN5093 as measured by the objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)

  • Conditions: nsclc
  • Phase: I/II
  • Trial ID: NCT04077099
  • Protocol ID: 19-506

Enrolling

NAUTIKA1: MULTICENTER, PHASE II, NEOADJUVANT AND ADJUVANT STUDY OF ALECTINIB, ENTRECTINIB, VEMURAFENIB PLUS COBIMETINIB, OR PRALSETINIB IN PATIENTS WITH STAGES II-III NON-SMALL CELL LUNG CANCER WITH ALK, ROS1, NTRK, BRAF V600, OR RET MOLECULAR ALTERATIONS

Trial Description: This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors that meet protocol-specified biomarker criteria

  • Conditions: non-small cell lung cancer
  • Phase: II
  • Trial ID: NCT04302025
  • Protocol ID: 20-098

Not Enrolling

A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAFV600E-mutant Non-small Cell Lung Cancer

Trial Description: This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in combination with binimetinib in patients with BRAFV600E-mutant metastatic non-small cell lung cancer (NSCLC). Patients who are either treatment-naïve, OR who have received 1) first-line treatment with standard platinum-based chemotherapy, OR 2) first-line treatment with an anti-programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) inhibitor given alone or in combination with platinum-based chemotherapy will be enrolled.

  • Conditions: non-small cell lung cancer
  • Phase: II
  • Trial ID: NCT03915951
  • Protocol ID: 19-252

Not Enrolling

A Phase 1 Dose Escalation and Expanded Cohort Study of PF-06821497 in the Treatment of Adult Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL)

Trial Description: A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 In The Treatment Of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) And Follicular Lymphoma (FL).

  • Conditions: castration resistant prostate cancer (crpc), follicular lymphoma (fl), small cell lung cancer (sclc)
  • Phase: I
  • Trial ID: NCT03460977
  • Protocol ID: 18-159

Not Enrolling

S1400, A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer LUNGMAP, “A Biomarker-Driven Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer S1400F, A Phase II Study of MEDI4736 (Durvalumab) plus T

Trial Description: This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid ?Master Protocol? (S1400). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes a ?non-match? sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of care also with the goal of approval.

  • Conditions: recurrent squamous cell lung carcinoma, stage iv squamous cell lung carcinoma ajcc v7
  • Phase: II/III
  • Trial ID: NCT02154490
  • Protocol ID: 14-416

Not Enrolling

Phase II Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients with Radiation Pneumonitis

Trial Description: The purpose of this study is to find out what effects, good and/or bad, the drug nintedanib in combination with steroids, has on the lungs. Furthermore, such treatments' side effects will be studied together with quality of life. In addition, the investigators would like to determine whether they can find markers in the blood which predict worsening lung injury.

  • Conditions: lung cancer, lung metastases
  • Phase: II
  • Trial ID: NCT02496585
  • Protocol ID: 17-360

Not Enrolling

A Phase 1b Study of Abemaciclib in Combination with Pembrolizumab for Patients with Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer

Trial Description: The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone receptor positive (HR+), human epidermal growth factor receptor negative (HER2-) breast cancer.

  • Conditions: breast cancer, non small cell lung cancer
  • Phase: II
  • Trial ID: NCT02779751
  • Protocol ID: 16-216

Not Enrolling

An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced solid/metastatic tumours

Trial Description: A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours.

  • Conditions: advanced solid tumors, metastatic breast cancer, metastatic castration-resistant prostate cancer, non-small cell lung cancer
  • Phase: I/II
  • Trial ID: NCT03568656
  • Protocol ID: 21-430

Enrolling

Phase II trial of neoadjuvant and adjuvant capmatinib in participants with stages IB-IIIA, N2 and selected IIIB (T3N2 or T4N2) NSCLC with MET exon 14 skipping mutation or high MET amplification – Geometry-N

Trial Description: The purpose of this study is to determine if neoadjuvant capmatinib can improve outcomes in participants with stages I-IIIA non-small cell lung cancer with MET exon 14 mutations and/or high MET amplification beyond those achieved with surgery, chemotherapy, and radiation.

  • Conditions: non-small cell lung cancer
  • Phase: II
  • Trial ID: NCT04926831
  • Protocol ID: 21-631

Not Enrolling

A Phase I Trial of AZD9291 and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer after Progression on a Previous EGFR Tyrosine Kinase Inhibitor

Trial Description: This phase I trial studies the side effects and best dose of necitumumab when given together with osimertinib in treating patients with EGFR-mutant non-small cell lung cancer that is stage IV or has come back (recurrent) and who have progressed on a previous EGFR tyrosine kinase inhibitor. Immunotherapy with monoclonal antibodies, such as necitumumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving necitumumab with osimertinib may be a better treatment for EGFR-mutant non-small cell lung cancer.

  • Conditions: metastatic lung non-small cell carcinoma, recurrent lung non-small cell carcinoma, stage iv lung non-small cell cancer ajcc v7
  • Phase: I
  • Trial ID: NCT02496663
  • Protocol ID: 16-726

Enrolling

CHIO3 Trial: Chemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

Trial Description: This is a single arm, phase II trial of combined neoadjuvant platinum doublet chemotherapy plus durvalumab followed by surgery, postoperative radiation and adjuvant durvalumab for 13 cycles for patients with potentially resectable stage IIIA and IIIB (T1-3, N2) NSCLC (per the 8th International Association for the Study of Lung Cancer classification). The primary objective of this study is to increase N2 nodal clearance (N2NC) to 50% or greater for combined platinum doublet chemotherapy with durvalumab induction therapy from historical rate of 30% for platinum doublet chemotherapy alone in patients with potentially resectable stage IIIA/B (N2) NSCLC.

  • Conditions: stage iiia non-small cell lung cancer, stage iiib non-small cell lung cancer
  • Phase: II
  • Trial ID: NCT04062708
  • Protocol ID: 20-642

Enrolling

A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Saftey, Tolerability, and Pharmacokinetics of HPN328 in Patients with Advanced Cancers Associated with Expression of Delta-Like Canonical Notch Ligand 3 (DLL3) Who Have Failed Standard Available Therapy.

Trial Description: An open-label, Phase 1/2 study of HPN328 as monotherapy to assess the safety, tolerability and PK in patients with advanced cancers associated with expression of DLL3.

  • Conditions: small-cell lung cancer
  • Phase: I/II
  • Trial ID: NCT04471727
  • Protocol ID: 20-751

Enrolling

A Phase 1 Study of ABBV-011 as a Single-Agent and in Combination with Budigalimab (ABBV-181) in Subjects with Relapsed or Refractory Small Cell Lung Cancer

Trial Description: This is a multicenter, open-label, Phase 1 study of ABBV-011 given as a single agent and in combination with budigalimab (ABBV-181) in participants with relapsed or refractory small cell lung cancer (SCLC). The study consists of 4 parts: Part A is a single-agent ABBV-011 dose regimen finding cohort; followed by Part B, a single-agent ABBV-011 dose expansion cohort; and then Part C, an ABBV-011 and budigalimab (ABBV-181) combination escalation and expansion cohort; Part D, single-agent ABBV-011 dose-evaluating cohort for Japan.

  • Conditions: small cell lung cancer
  • Phase: I
  • Trial ID: NCT03639194
  • Protocol ID: 19-037

Not Enrolling

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Trial Description: This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). Eligible participants will be stratified by Eastern Cooperative Oncology Group (ECOG) Performance Status (0 vs. 1), LDH (= upper limit of normal [ULN] vs. > ULN), and presence or history of brain metastasis (yes vs. no) and randomly assigned in a 1:1 ratio to receive one of the following treatment regimens during induction phase: - Arm A: Tiragolumab plus atezolizumab plus CE - Arm B: Placebo plus atezolizumab plus CE Following the induction phase, participants will continue maintenance therapy with either atezolizumab plus tiragolumab (Arm A) or atezolizumab plus placebo (Arm B).

  • Conditions: small cell lung cancer
  • Phase: III
  • Trial ID: NCT04256421
  • Protocol ID: 19-882

Enrolling

A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF LURBINECTEDIN IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH ATEZOLIZUMAB AS MAINTENANCE THERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (ES-SCLC) FOLLOWING FIRST-LINE INDUCTION THERAPY WITH CARBOPLATIN, ETOPOSIDE AND ATEZ

Trial Description: Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab alone administered as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) after first-line induction therapy with carboplatin, etoposide, and atezolizumab. The study consists of 2 phases: an induction phase and a maintenance phase. Participants need to have an ongoing response or stable disease per the Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 criteria after completion of 4 cycles of carboplatin, etoposide, and atezolizumab induction treatment in order to be considered for eligibility screening for the maintenance phase. Eligible participants will be randomized in a 1:1 ratio to receive either lurbinectedin plus atezolizumab or atezolizumab in the maintenance phase.

  • Conditions: small-cell lung cancer
  • Phase: III
  • Trial ID: NCT05091567
  • Protocol ID: 22-003

Not Enrolling

A Multi-Center, Phase IB/II Study of Combination Treatment of APG-1252 with Paclitaxel in Patients with Relapsed/Refractory Small Cell Lung Cancer

Trial Description: This is a multi-center, open-label, phase Ib/II study of combination therapy with APG-1252 plus paclitaxel in patients with relapsed/refractory small-cell lung cancer(SCLC). The phase Ib portion will be done using time-to-event continual reassessment method (TITE-CRM) methodology to determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of APG-1252 with a fixed dose of paclitaxel. The phase II portion will utilize a Simon two-stage design to determine the efficacy of the combination therapy with response rate as the primary endpoint.

  • Conditions: small cell lung cancer
  • Phase: I/II
  • Trial ID: NCT04210037
  • Protocol ID: 20-055

Enrolling

A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Trial Description: This Phase 2 study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment

  • Conditions: advanced non-small cell lung cancer, metastatic non-small cell lung cancer
  • Phase: II
  • Trial ID: NCT04613596
  • Protocol ID: 21-244

Enrolling

Stereotactic radiation in patients with small cell lung cancer and 1-6 brain metastases: A single arm, phase II trial

Trial Description: This research study is studying stereotactic radiation (focused/pinpoint radiation that targets each individual tumor but not the surrounding brain) instead of whole-brain radiation (radiation targeting the entire brain) as a possible treatment for patients with small cell lung cancer and 1-10 brain metastases. The intervention involved in this study is: -Stereotactic (focused, pinpoint) radiation

  • Conditions: brain metastases, small cell lung cancer
  • Phase: II
  • Trial ID: NCT03391362
  • Protocol ID: 17-550

Enrolling

A Phase 1 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non-Small Cell Lung Cancer

Trial Description: This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of BDTX-1535 in patients with GBM or NSCLC harboring sensitive EGFR alterations and who have disease progression following standard of care

  • Conditions: glioblastoma, non-small cell lung cancer
  • Phase: I
  • Trial ID: NCT05256290
  • Protocol ID: 22-295